Abstract 603
Background
Observational studies show that Alzheimer’s disease (AD) and lung cancer is negatively associated in both directions. However, whether there is a causal relationship between AD and lung cancer remains uncertain. Mendelian Randomization (MR) is a novel approach for the assessment of causality, using genome-wide significant single-nucleotide polymorphisms (SNP) as instrument variables (IV) to eliminate the bias caused by confounders. In this study, we utilized a bi-directional two-sample MR analysis to estimate the potential causality between AD and lung cancer.
Methods
The genome-wide association study (GWAS) summary data of AD and lung cancer were derived from the International Genomics of Alzheimer’s Project (IGAP,17,008 AD cases and 37,154 controls) and the International Lung Cancer Consortium (ILCCO, 11,348 lung cancer cases and 15,861 controls), respectively. We performed a bi-directional two-sample MR analysis to determine the causal relationship between AD and lung cancer. To be specific, Inverse-Variance Weighted (IVW), MR-Egger and Weighted Median methods were utilized for deriving causal estimates. Single SNP analysis and leave-one-out analysis were also conducted to identify if a single SNP is driving the association. We also performed the MR-Egger regression and MR-PRESSO analysis for the evaluation of horizontal pleiotropy.
Results
There was no causal relationship between AD and lung cancer in bi-directional MR. The results of Single SNP analysis and leave-one-out analysis indicated that no single SNP was driving the association. No directional horizontal pleiotropy was detected in the MR-Egger regression analysis. The MR-PRESSO analysis did not detect horizontal pleiotropy. There was no evidence for violations of MR assumptions in the sensitivity analysis.Table:
1847P Mendelian randomization estimates of the causality
Exposure | Outcome | Inverse Variance Weighted | MR Egger | Weighted Median | |||
---|---|---|---|---|---|---|---|
OR (95%CI) | P-value | OR (95%CI) | P-value | OR (95%CI) | P-value | ||
Alzheimer’s Disease | Lung Cancer | 1.040 (0.965-1.121) | 0.299 | 1.033 (0.890-1.199) | 0.676 | 0.999 (0.902-1.106) | 0.980 |
Lung Cancer | Alzheimer’s Disease | 0.919 (0.794-1.062) | 0.253 | 1.223 (0.597-2.504) | 0.637 | 0.920 (0.836-1.013) | 0.091 |
Conclusions
We found no causality between AD and lung cancer through the two-sample MR analysis. However, further study is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key R&D Program of China (Grant No. 2016YFC0905500, 2016YFC0905503).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2066 - Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first line (1L) immuno-oncology (IO) monotherapy (mono tx)
Presenter: Denis Talbot
Session: Poster Display session 1
Resources:
Abstract
5919 - Real-world effectiveness of nivolumab monotherapy after prior systemic therapy in advanced non-small cell lung cancer (NSCLC) in the United States
Presenter: David Stenehjem
Session: Poster Display session 1
Resources:
Abstract
3368 - Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population
Presenter: Nikolaj Frost
Session: Poster Display session 1
Resources:
Abstract
3775 - Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany. Treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315)
Presenter: Frank Griesinger
Session: Poster Display session 1
Resources:
Abstract
3926 - Impact of second-line (2L) immune checkpoint inhibitors (ICIs) on the treatment (Tx) of advanced non-small cell lung cancer (NSCLC) in a UK centre: a REAL-Oncology analysis from the I-O Optimise initiative
Presenter: Michael Snee
Session: Poster Display session 1
Resources:
Abstract
5068 - First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort
Presenter: Karim Amrane
Session: Poster Display session 1
Resources:
Abstract
1182 - Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small-cell lung cancer patients
Presenter: Teppei Sugano
Session: Poster Display session 1
Resources:
Abstract
2297 - Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)
Presenter: Yosuke Kawashima
Session: Poster Display session 1
Resources:
Abstract
2739 - Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
Presenter: Christian Grohe
Session: Poster Display session 1
Resources:
Abstract
1357 - Upfront atezolizumab chemoimmunotherapy-associated Immune-related adverse events in patients with advanced non-small cell lung cancer
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract